


LIVE SIMULCAST\*



# 7<sup>th</sup> Annual Hematology and Medical Oncology Board Review:

CONTEMPORARY PRACTICE

MARCH 8-11, 2019



Memorial Sloan Kettering  
Cancer Center

# 7<sup>th</sup> Annual Hematology and Medical Oncology Board Review: CONTEMPORARY PRACTICE

## COURSE OVERVIEW

This four day course will provide an up-to-date and comprehensive review of the diagnosis, staging, and management of neoplastic disease, including solid tumor and hematologic oncology. Lectures will focus on disease specific topics in gastrointestinal, gynecologic, thoracic, head and neck, genitourinary, soft tissue and skin, and central nervous system oncology, as well as hematologic oncology.

### Target Audience

The target audience for this course is medical oncology professionals, including physicians, nurses, pharmacists, fellows and residents.

### Educational Objectives

- Learn state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers
- Learn state-of-the-science in diagnosis, staging, and therapeutic management of hematologic cancers
- Understand recent treatment advances in solid tumor and hematologic oncology and their impact on modern clinical practice

### MSK Course Directors



#### David H. Ilson, MD, PhD

Attending Physician, Gastrointestinal Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine  
Member, Memorial Sloan Kettering Cancer Center  
Professor of Medicine, Weill Cornell Medical College



#### Paul A. Hamlin, MD

Medical Director, David H. Koch Center for Cancer Care  
Associate Attending, Lymphoma Service  
Division of Hematologic Malignancies  
Department of Medicine  
Associate Professor of Medicine, Weill Cornell Medical College

### MSK Course Faculty

#### Ghassan K. Abou-Alfa, MD, MBA

Attending Physician  
Gastrointestinal Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Carol Aghajanian, MD

Attending Physician, Chief  
Gynecologic Medical Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Dean F. Bajorin, MD, FACP

Attending Physician  
Genitourinary Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Renier J. Brentjens, MD, PhD

Director, Cellular Therapeutics Center  
Associate Attending  
Leukemia Service  
Division of Hematologic Oncology  
Department of Medicine

#### Andrea Cercek, MD

Assistant Attending Physician  
Gastrointestinal Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Paul B. Chapman, MD

Attending Physician  
Melanoma and Immunotherapeutics service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Hiram S. Cody III, MD, FACS

Attending Surgeon  
Breast Service  
Department of Surgery  
Professor of Surgery, Weill Cornell Medical College

#### Chau T. Dang, MD

Chief, West Harrison Medical  
Oncology Service  
Breast Medicine Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Mark A. Dickson, MD

Associate Attending Physician  
Sarcoma Medical Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Darren R. Feldman, MD

Assistant Attending Physician  
Genitourinary Oncology Service  
Bone Marrow Transplant Service  
Assistant Professor of Medicine, Weill Cornell Medical College

#### Devika Gajria, MD

Assistant Attending  
Breast Medicine Service  
Department of Medicine

#### Rachel N. Grisham, MD

Assistant Attending Physician  
Gynecologic Medical Oncology Service  
Department of Medicine

#### Mrinal M. Gounder, MD

Assistant Attending Physician  
Sarcoma Medical Oncology Service  
Early Drug Development Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Christian Grommes, MD

Assistant Attending Physician  
Brain Tumor Service  
Department of Neurology

#### Komal Jhaveri, MD, FACP

Attending  
Breast Medicine Service and Early Drug Development Service  
Department of Medicine

#### Philip Kantoff, MD

Chairman, Department of Medicine  
Professor of Medicine, Weill Cornell Medical College

#### C. Ola Landgren, MD, PhD

Chief, Myeloma Service  
Division of Hematologic Oncology  
Department of Medicine

#### Bob T. Li, MD, MPH

Assistant Attending Physician  
Thoracic Oncology Service  
Developmental Therapeutics  
Division of Solid Tumor Oncology  
Department of Medicine

#### Simon Mantha, MD, MPH

Associate Attending Physician  
Hematology Service  
Division of Hematologic Oncology  
Department of Medicine

#### Michael J. Mauro, MD

Attending Physician  
Leukemia Service  
Division of Hematologic Oncology  
Department of Medicine

#### Beryl McCormick, MD, FACP

Chief, External Beam  
Radiotherapy Service  
Department of Radiation Oncology  
Professor of Radiation Oncology, Weill Cornell Medical College

#### Jodi Mones, MD

Associate Attending  
Hematology Service  
Division of Hematologic Oncology  
Department of Medicine

#### Alison J. Moskowitz, MD

Clinical Director, Lymphoma Inpatient Unit  
Assistant Attending  
Lymphoma Service  
Department of Medicine

#### Robert J. Motzer, MD

Attending Physician  
Genitourinary Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Eileen M. O'Reilly, MD

Associate Director for Clinical Research,  
David M. Rubenstein Center for Pancreatic Cancer  
Attending Physician  
Gastrointestinal Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine  
Member, Memorial Sloan Kettering Cancer Center  
Professor of Medicine, Weill Cornell Medical College

#### Rekha Parameswaran, MD

Associate Attending  
Hematology Service  
Department of Medicine

#### David G. Pfister, MD

Attending Physician, Chief  
Head and Neck Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Gregory J. Riely, MD, PhD

Vice Chair, Clinical Research  
Associate Attending Physician  
Thoracic Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Leonard B. Saltz, MD

Executive Director for Clinical Value and Sustainability  
Attending Physician  
Gastrointestinal Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine  
Professor of Medicine, Weill Cornell Medical College

#### Craig S. Sauter, MD

Assistant Attending  
Bone Marrow Transplant Service  
Department of Medicine

#### Susan Seo, MD

Attending Physician  
Infectious Disease service  
Division of General Medicine  
Department of Medicine

#### Gerald A. Soff, MD

Chief, Hematology Service  
Division of Hematologic Oncology  
Department of Medicine

#### Zsafia K. Stadler, MD

Clinical Director, Clinical Genetics Service  
Associate Attending Physician  
Clinical Genetics and Gastrointestinal Oncology Services  
Division of Solid Tumor Oncology  
Department of Medicine

#### Martin S. Tallman, MD

Chief, Leukemia Service  
Division of Hematologic Oncology  
Department of Medicine

#### Anna M. Varghese, MD

Assistant Attending Physician  
Gastrointestinal Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Marjorie G. Zauderer, MD

Co-Director MSK Mesothelioma Program  
Assistant Attending Physician  
Thoracic Oncology Service  
Division of Solid Tumor Oncology  
Department of Medicine

#### Andrew D. Zelenetz, MD, PhD

Medical Director, Quality Informatics  
Attending Physician  
Lymphoma Service  
Division of Hematologic Oncology  
Department of Medicine

**Day 1 | Friday, March 8**

**Solid Tumor Session**

9:00 AM	<b>Colon Cancer</b>	Leonard B. Saltz, MD
10:00 AM	<b>Melanoma</b>	Paul B. Chapman, MD
10:45 AM	<b>Prostate Cancer</b>	Philip Kantoff, MD
11:30 AM	<b>Kidney Cancer</b>	Robert J. Motzer, MD
12:15 PM	<b>Mesothelioma</b>	Marjorie G. Zauderer, MD
12:30 PM	Lunch	
1:15 PM	<b>Urothelial Cancer</b>	Dean F. Bajorin, MD, FACP
2:00 PM	<b>Testis Cancer</b>	Darren R. Feldman, MD
2:45 PM	<b>Uterine/Cervix/Other GYN Cancers</b>	Carol Aghajanian, MD
3:30 PM	Break	
3:45 PM	<b>Ovarian Cancer</b>	Rachel N. Grisham, MD
4:30 PM	<b>Breast Cancer/Surgery</b>	Hiram S. Cody III, MD, FACS
5:00 PM	<b>Breast Cancer/Radiation Therapy</b>	Beryl McCormick, MD, FACR
5:30 PM	<b>Esophageal and Gastric Cancer</b>	David H. Ilson, MD, PhD
6:00 PM	Adjourn	

**Day 2 | Saturday, March 9**

7:00 AM	<b>Small Cell Lung Cancer</b>	Bob T. Li, MD, MPH
7:30 AM	<b>Breast Cancer/Advanced Disease</b>	Komal Jhaveri, MD, FACP
8:30 AM	<b>Breast Cancer/Adjuvant Therapy</b>	Chau T. Dang, MD
9:30 AM	<b>Breast Cancer/Hormonal Therapy</b>	Devika Gajria, MD
10:00 AM	<b>Carcinoma of Unknown Primary</b>	Anna M. Varghese, MD
10:30 AM	Break	
10:45 AM	<b>Hepatocellular Cancer and Cholangiocarcinoma</b>	Ghassan K. Abou-Alfa, MD, MBA
11:30 AM	<b>Pancreatic and Neuroendocrine Cancer</b>	Eileen M. O'Reilly, MD
12:15 PM	Lunch	
1:15 PM	<b>Non Small Cell Lung Cancer</b>	Gregory J. Riely, MD, PhD
2:00 PM	<b>Head and Neck, Thyroid Cancer</b>	David G. Pfister, MD
2:45 PM	<b>Anal/Rectal Cancer</b>	Andrea Cercek, MD
3:15 PM	Break	

3:30 PM	<b>Genetics</b>	Zsofia K. Stadler, MD
4:00 PM	<b>CNS Tumors</b>	Christian Grommes, MD
4:30 PM	<b>Sarcoma</b>	Mark A. Dickson, MD
5:00 PM	<b>Infectious Disease</b>	Susan Seo, MD
5:30 PM	Adjourn	

**Day 3 | Sunday, March 10**

**Pharmacology Session**

7:30 AM	<b>Pharmacology I</b>	Mrinal M. Gounder, MD
8:15 AM	<b>Pharmacology II</b>	Mrinal M. Gounder, MD
9:20 AM	Break	

**Hematology Session**

9:30 AM	<b>Thrombocytopenia, ITP and Beyond</b>	Gerald Soff, MD
10:30 AM	<b>Low Grade NHL/CLL</b>	Andrew D. Zelenetz, MD, PhD
11:30 AM	<b>DLBCL/MCL/BL</b>	Paul Hamlin, MD
12:30 PM	Lunch	
1:15 PM	<b>HL/T Cell</b>	Alison J. Moskowitz, MD
2:15 PM	<b>Auto/Allo</b>	Craig S. Sauter, MD
3:15 PM	<b>AML/ALL</b>	Martin S. Tallman, MD
4:15 PM	Break	
4:30 PM	<b>MDS/MPN</b>	Michael J. Mauro, MD
5:30 PM	<b>Myeloma/Amyloid</b>	C. Ola Landgren, MD, PhD
6:30 PM	Adjourn	

**Day 4 | Monday, March 11**

8:00 AM	<b>CART cells</b>	Renier J. Brentjens, MD, PhD
9:00 AM	<b>The Role of the Direct Oral Anticoagulants in Practice</b>	Simon Mantha, MD, MPH
10:00 AM	<b>Approach to The Bleeding Patient</b>	Rekha Parameswaran, MD
11:00 AM	<b>Sickle Cell Disease, Thalassemia</b>	Jodi Mones, MD
12:00 PM	Adjourn	

# REGISTRATION

---

**Live Simulcast Fee**

**\$1,700**

Register online:  
[mskcc.org/HemOncBoardReview](https://mskcc.org/HemOncBoardReview)

You will receive detailed instructions via email prior to the start of the course. This will include information on how to engage with the faculty as well as information on how to claim CME credits - active participation throughout the live simulcast is encouraged. For inquiries regarding the simulcast, please email [cme@mskcc.org](mailto:cme@mskcc.org).

- **MSK CME offers a 30% discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners.** If you are a member of one of these groups, please contact [cme@mskcc.org](mailto:cme@mskcc.org) for more information.
- **MSK employee are welcome to attend this course in person.** The live simulcast is available for non-MSK employees only. To register for the live course, please visit [mskcc.org/HemOncBoardReview](https://mskcc.org/HemOncBoardReview).

## Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.



## AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **30.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **30.75 Medical Knowledge MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

## Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.